Goldman analyst Salveen Richter comments on Sarepta Therapeutics (NASDAQ: SRPT) saying "SRPT presented positive preclinical data from its next-gen PPMO ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE